Search the Site

Twitter

test tubes

$KERX Keryx Faces Key Litmus Test with Phase 3 Efficacy Results on Tuesday for Zerenex

publication date: Nov 29, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Written by Mike Havrilla. Keryx Biopharma (NASDAQ: KERX) is an emerging, small-cap biopharma company that has a pair of lead compounds in late-stage, Phase 3 development for the treatment of cancer (perifosine) and renal disease (Zerenex) under Special Protocol Assessment (SPA) agreements with the FDA. After the market close, KERX announced it will host a conference call Tuesday morning at 830am (ET) to review top-line results from a pivotal Phase 3 short-term efficacy study for Zerenex (ferric citrate).



Sorry this page is available to subscribers only. If you're not a subscriber why not join today?

You can also sign up for our 100% FREE Newsletter  to stay current on public webinars, special offers, and news alerts:

FREE NEWSLETTER

If you are already a subscriber, please login.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site including:

- Detailed Reports on Upcoming FDA and Clinical Trial Trades
- REAL TIME Posting of Trades (Entries and Exits)
- Clinical and Regualtory Catalyst Database with over 300 events and updated daily 
- Members Only Live Interactive Webinars 
- Weekly Watchlist
- Email / SMS (Text Message) Alerts of critical news
- Access to view Mark Messier and Mike Havrilla's Trading Accounts
- A More Detailed FDA Calendar
- Direct Email Communication
- Affiliate Program

If you believe you should be able to view this area then please contact us and we will try to rectify this issue as soon as possible.